Literature DB >> 6703855

Serotonin function and mechanism of action of antidepressant treatment. Effects of amitriptyline and desipramine.

D S Charney, G R Heninger, D E Sternberg.   

Abstract

The effects of amitriptyline hydrochloride and desipramine hydrochloride treatment on brain serotonin (5-HT) function were investigated in 21 patients. The ability of an intravenous infusion of the serotonin precursor tryptophan to raise serum prolactin (PRL) levels was determined in 13 depressed patients during placebo administration and after 28 to 35 days of treatment with either amitriptyline or desipramine. Both desipramine (N = 7) and amitriptyline (N = 6) significantly increased the PRL rise induced by tryptophan compared with a preceding placebo period. In contrast, following long-term amitriptyline and desipramine treatment, the ability of tryptophan to increase PRL was enhanced two weeks following abrupt cessation of amitriptyline therapy (N = 5), but not after discontinuation of desipramine therapy. The results of this investigation are consistent with electrophysiologic and behavioral studies in laboratory rats and suggest that desipramine- and amitriptyline-induced alterations in 5-HT function may be related to their antidepressant mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703855     DOI: 10.1001/archpsyc.1984.01790150049008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  18 in total

Review 1.  Utilization and mechanism of action of tricyclic antidepressants in the treatment of chronic facial pain: a review of the literature.

Authors:  R S Brown; W K Bottomley
Journal:  Anesth Prog       Date:  1990 Sep-Oct

2.  Hormonal and behavioral effects associated with intravenous L-tryptophan administration.

Authors:  A Winokur; N D Lindberg; I Lucki; J Phillips; J D Amsterdam
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.

Authors:  Flora Coker; David Taylor
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

4.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  The plus maze and scototaxis test are not valid behavioral assays for anxiety assessment in the South African clawed frog.

Authors:  R Boone Coleman; Kelsey Aguirre; Hannah P Spiegel; Celina Pecos; James A Carr; Breanna N Harris
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2019-05-29       Impact factor: 1.836

6.  Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man.

Authors:  H D Mühlbauer; B Müller-Oerlinghausen
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 7.  Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain.

Authors:  P Blier; F V Abbott
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

8.  Clomipramine enhances prolactin and growth hormone responses to L-tryptophan.

Authors:  I M Anderson; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Evaluation of indole-based probes for high-throughput screening of drug binding to human serum albumin: Analysis by high-performance affinity chromatography.

Authors:  Mandi L Conrad; Annette C Moser; David S Hage
Journal:  J Sep Sci       Date:  2009-04       Impact factor: 3.645

10.  Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline.

Authors:  C S Aulakh; J L Hill; K M Wozniak; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.